drugset / Trial / NCT05679336
Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy
NaSingle-groupOpen-labelTreatment
Summary
This exploratory study aims to assess the efficacy, safety of the experimental treatment based on a combination of rituximab (RTX), intravenous (IV) cyclophosphamide (CYC), and corticosteroids (S) administrated at lower cumulative doses (RCP) for the induction of early remission in subjects with anti-PLA2R antibody-positive primary membranous nephropathy (PMN) having nephrotic syndrome (NS).
Timeline
- Start
- 2018-05-01
- Primary completion
- 2024-08-31
- Completion
- 2024-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 7.5 mg/kg | Intravenous |
| Subject | Methylprednisolone | Other / unclassified | 500 mg | Intravenous |
| Subject | Prednisolone | Other / unclassified | 5 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |